Guru Sonpavde
Harvard University
CancerInternal medicineUrologySurgeryOncologyRandomized controlled trialCystectomyChemotherapyRenal cell carcinomaCarcinomaCisplatinProstate cancerBladder cancerDocetaxelMetastatic Urothelial CarcinomaIn patientUrothelial carcinomaCancer researchClinical trialMedicinePharmacology
756Publications
60H-index
11.7kCitations
Publications 751
Newest
INTRODUCTION AND OBJECTIVE:Radiation associated muscle-invasive bladder cancer (RA-MIBC) is a potentially lethal late toxicity following definitive radiation for prostate cancer. RA-MIBC can be dif...
Source
#1Catherine Curran (Harvard University)H-Index: 5
#2Elio Adib (Harvard University)H-Index: 2
Last. Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 13
view all 14 authors...
ABSTRACT null null Background null Enfortumab vedotin (EV) is approved to treat metastatic urothelial carcinoma (mUC) following platinum and PD1/L1 inhibitors. Since the outcomes and patterns of therapy of patients following discontinuation of EV are unknown, we conducted a retrospective study to assess this issue. null null null Methods null Data were retrospectively obtained from patients with mUC following discontinuation of EV after prior platinum-based chemotherapy and PD1/L1 inhibitors. Ob...
Source
#1Andres M. Acosta (Brigham and Women's Hospital)H-Index: 8
#2Justine A. Barletta (Brigham and Women's Hospital)H-Index: 39
Last. Michelle S. Hirsch (Brigham and Women's Hospital)H-Index: 55
view all 5 authors...
Context.— Plasmacytoid urothelial carcinoma (PC-UC) is an aggressive variant of urothelial carcinoma (UC), characterized by loss of E-cadherin (E-Cad)-mediated intercellular adhesion. Loss of E-Cad by immunohistochemistry can help diagnosis PC-UC; however, sensitivity is limited. Expression of other cadherin-catenin adhesion complex members, that is, p-120 catenin (p-120) and β-catenin (B-Cat), which are diagnostically useful for lobular breast carcinoma, remains unknown in UC. Objective.— To de...
Source
#1Edwin Lin (HCI: Huntsman Cancer Institute)H-Index: 4
#2Andrew W. Hahn (University of Texas MD Anderson Cancer Center)H-Index: 2
Last. Guru Sonpavde (Harvard University)H-Index: 60
view all 16 authors...
PURPOSE Progression from metastatic castration-sensitive prostate cancer (mCSPC) to a castration-resistant (mCRPC) state heralds the lethal phenotype of prostate cancer. Identifying genomic alterations associated with mCRPC may help find new targets for drug development. In the majority of patients, obtaining a tumor biopsy is challenging because of the predominance of bone-only metastasis. In this study, we hypothesize that machine learning (ML) algorithms can identify clinically relevant patte...
Source
#1Alicia K. Morgans (NU: Northwestern University)H-Index: 21
#2Zsolt HeppH-Index: 1
Last. Guru Sonpavde (Harvard University)H-Index: 60
view all 7 authors...
Abstract null null Background null Several programmed death-1 or death-ligand 1 (PD-1/L1) inhibitors are approved first- or second-line therapies for locally advanced or metastatic urothelial carcinoma (la/mUC); however, clinical trials show that only ∼20% of patients respond and all ultimately progress. This study elucidated real-world treatment patterns, healthcare resource utilization (HRU), and economic burden among Medicare beneficiaries with la/mUC who discontinue PD-1/L1 inhibitor therapi...
Source
#1Eddy S. Yang (UAB: University of Alabama at Birmingham)H-Index: 34
#2Amin Nassar (Brigham and Women's Hospital)H-Index: 10
Last. Sumanta K. Pal (City of Hope National Medical Center)H-Index: 60
view all 12 authors...
Everolimus monotherapy use for metastatic clear cell-RCC (mRCC) has diminished due to recent approvals of immune checkpoint and VEGF inhibitors. We hypothesized that gene expression associated with everolimus benefit may provide rationale to select appropriate patients. To address this hypothesis, tumors from a phase I/II trial that compared everolimus alone or with BNC105P, a vascular disrupting agent (VDA), were profiled using Nanostring as a discovery cohort. A phase III trial (CheckMate 025)...
Source
#1Elio Adib (Harvard University)H-Index: 2
#2Amin Nassar (Harvard University)H-Index: 10
Last. David J. Kwiatkowski (Brigham and Women's Hospital)H-Index: 142
view all 16 authors...
PURPOSE Immune checkpoint inhibitors (ICI) have shown clinical benefit in many types of metastatic cancers with only a few predictive biomarkers identified so far. CDKN2A is commonly altered in human cancers, but prior studies have provided conflicting evidence regarding the association between CDKN2A genomic alterations (GA) and response to ICIs. Herein, we examined the impact of loss-of-function CDKN2A alterations on response and survival in patients treated with ICIs. EXPERIMENTAL DESIGN We s...
Source
Source
Source
Source